echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > New evidence of RSV long-acting antibody protection

    New evidence of RSV long-acting antibody protection

    • Last Update: 2022-08-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Sanofi today announced that an analysis of data from the latest clinical trial of nirsevimab, a long-acting antibody therapy for respiratory syncytial virus (RSV), shows that in children entering their first RSV season, nirsevimab will reduce the need for treatment due to RSV infecti.


    RSV is a common infectious agent that causes seasonal epidemics of LRTI, including bronchitis and pneumonia, and is the leading cause of hospitalization in infants worldwi.


    This pre-specified meta-analysis pooled data from the pivotal Phase 3 clinical trial MELODY and the Phase 2b clinical tri.


    Another post hoc analysis found that nirsevimab-treated infants had blood levels of RSV-neutralizing antibodies 50 times higher than baseline levels after 151 da.


    "RSV remains the most common cause of LRTI in infants, causing seasonal epidemics each ye.


    References:

    [1] Press Release: New nirsevimab data analyses reinforce efficacy against R.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.